WARF Therapeutics will guide researchers through the process of pre-submission, submission, portfolio review, prioritization and program execution.
Here’s how we improve public health together: WARF Therapeutics. Research. Invest. Develop. That may sound like a common approach to drug discovery, but WARF Therapeutics adds a valuable twist through its virtual drug discovery laboratory developed in partnership with Pharmaron, Sai Life Sciences, GFree Bio, Viva Biotech, LIDE Biotech and others.
Partnering with both UW-Madison and Morgridge Institute for Research Principal Investigators, WARF Therapeutics creates a translational research path that taps world-renowned research and an industry-focused approach to improve value propositions of drug candidates.
Driven by a dedication to accelerating cures and improving therapies, the WARF Therapeutics team utilizes a disciplined application of drug discovery resources and stage gate milestones. This process moves programs towards optimized novel molecules that demonstrate in vivo proof of concept and support the therapeutic hypothesis.
Then, WARF Therapeutics leverages an array of solutions including licensing, investment, partnerships or startup companies to advance suitable drug candidates testing. Our portfolio consists of programs that have achieved a high degree of preclinical validation, span a spectrum of therapeutic areas, and are focused on improving the lives of patients with unmet medical needs.
This strategic initiative and investment moves validated targets to a high value developed chemical asset complete with a compelling preclinical data package. In doing so, WARF Therapeutics: